MENUNews Archive
Date: 06/05/2017
New research explains why this difficult-to-treat disease becomes resistant to chemotherapy, suggesting potential future treatment options.
Date: 06/05/2017
In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, a new study finds.
Date: 06/04/2017
A new analysis finds that nearly three-quarters of 500 patients with advanced cancer could be referred to a potential targeted treatment based on the results of a comprehensive analysis of their tumor’s genetic landscape.
Date: 06/01/2017
Daniel Hayes, M.D., Clinical Director of the Breast Oncology Program in the University of Michigan Rogel Cancer Center, discusses the results of trials involving the use of anti-estrogen therapy for more than five years for breast cancer patients.
Date: 05/24/2017
Triple-negative is the most aggressive kind of breast cancer. Triple negative tumors are negative for estrogen receptor, progesterone receptor and the HER2 protein. Because treatments that target these proteins would not work in triple negative breast cancer, the main treatment for it is chemotherapy.